Atypical bullous erythrodysesthesia mimicking fixed drug eruption during cabozantinib therapy: a case report

Nurcan Metin; Hatice Korkmaz

doi:10.18203/issn.2454-2156.IntJSciRep20262821

Authors

Nurcan Metin Department of Dermatology and Venereology, Health Sciences University Erzurum City Hospital, Erzurum, Republic of Turkey
Hatice Korkmaz Department of Dermatology and Venereology, Health Sciences University Erzurum City Hospital, Erzurum, Republic of Turkey

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20262821

Keywords:

Cabozantinib, Renal cell carcinoma, Bullous erythrodysesthesia, Fixed drug eruption

Abstract

Cabozantinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma. Palmar-plantar erythrodysesthesia (PPES) is a well-recognized cutaneous adverse effect of tyrosine kinase inhibitors; however, atypical bullous presentations are extremely rare. We report a 79-year-old man who developed painful, pruritic, well-demarcated bullous lesions on the distal fingers of both hands and the left heel three weeks after initiating cabozantinib therapy. Unlike classic PPES, the lesions consisted of tense bullae without hyperkeratosis and closely resembled bullous fixed drug eruption. This case highlights a rare presentation of cabozantinib-induced bullous erythrodysesthesia that mimics fixed drug eruption. Awareness of this uncommon adverse reaction is important for accurate diagnosis, appropriate treatment modification, and avoidance of unnecessary diagnostic procedures.

References

Hasan AA, Masuo Y, Fujita KI, Shimada K, Iida N, Wakayama T, et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition. Biochem Pharmacol. 2022;197:114914. DOI: https://doi.org/10.1016/j.bcp.2022.114914

Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 2015;151(2):170-7. DOI: https://doi.org/10.1001/jamadermatol.2014.2734

National Institute for Health and Care Excellence (NICE). Cabozantinib for previously treated advanced renal cell carcinoma. NICE Technology Appraisal Guidance [TA463]. London: NICE; 2018.

Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (“hand-foot”) syndrome: incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-34. DOI: https://doi.org/10.2165/00128071-200001040-00004

Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11(3):238-46. DOI: https://doi.org/10.1016/j.ejon.2006.10.004

Growcott S, Banner A, Bray A, Hilman S. A rare cutaneous adverse effect secondary to cabozantinib therapy. Oxf Med Case Rep. 2018;2018(12):omy105. DOI: https://doi.org/10.1093/omcr/omy105

Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592-6. DOI: https://doi.org/10.1111/j.1365-2133.2007.08357.x

Lee AY. Fixed drug eruptions: incidence, recognition, and avoidance. Am J Clin Dermatol. 2000;1(5):277-85. DOI: https://doi.org/10.2165/00128071-200001050-00003

U.S. Food and Drug Administration. CABOMETYX™ (Cabozantinib) tablets, for oral use: Prescribing information. Silver Spring (MD): FDA; 2021.